Atrial Fibrillation Drugs Market Size By Products (Antiarrhythmic Drugs, Anticoagulant Drugs {Vitamin K Antagonists, Novel Oral Anticoagulants [Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors]}), By Atrial Fibrillation Type (Paroxysmal, Persistent, Permanent), By Application (Heart Rhythm Control, Heart Rate Control) By Route of Administration (Oral, Injectable) By End-use (Hospitals, Cardiac Centres, Ambulatory Surgical Centres) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Published Date: Apr 2019  |  Report ID: GMI3253  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 350   |   Base Year: 2018

Summary Table of Contents Industry Coverage Methodology

Industry Trends

Atrial Fibrillation Drugs Market size was valued at USD 13 billion in 2018 and is expected to witness 3% CAGR from 2019 to 2025.

Atrial Fibrillation Drugs Market

Get more details on this report - Request Free Sample PDF

Atrial fibrillation drugs market is expected to witness lucrative growth over the forecast period. Increasing rate of geriatric population coupled with rising prevalence of valvular diseases will augment the market growth. Moreover, increasing rate of population suffering from diabetes is another factor fueling the growth of atrial fibrillation drugs market. Increasing prevalence of cardiovascular diseases in emerging regions owing to rise in sedentary lifestyle and increasing habit of binge eating will fuel adoption rates in developing as well as certain developed countries.

However, drug side effects will be one of the major reasons hindering the adoption rates in few developing and under-developed countries. Drug side effects such as severe bleeding, tiredness, etc. will continue to hamper market growth over the forecast timeframe. Also, lack of awareness about recent medical drug therapies for the treatment of atrial fibrillation in certain emerging regions might hamper the market growth.

Atrial Fibrillation Drugs Market Report Coverage
Report Coverage Details
Base Year: 2018 Market Size in 2018: 13 Billion (USD)
Historical Data for: 2014 to 2018 Forecast Period: 2019 to 2025
Forecast Period 2019 to 2025 CAGR: 3% 2025 Value Projection: 17 Billion (USD)
Pages: 350 Tables, Charts & Figures: 728
Geographies covered (40): U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Poland, Switzerland, Belgium, Czech Republic, Netherlands, Sweden, Hungary, Austria, Portugal, Denmark, Norway, Finland, Ireland, Turkey, Greece, China, Japan, India, Australia, South Korea, Taiwan, New Zealand, Singapore, Brazil, Argentina, Venezuela, Columbia, Mexico, South Africa, Saudi Arabia, UAE, Egypt
Segments covered: Products, Atrial Fibrillation Type, Application, Route of Administration, End-use and Region
Companies covered (10): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Johnson and Johnson (JanssenOrtho), Mitsubishi Tanabe Pharma, Pfizer, Portola Pharmaceuticals, Sanofi
Growth Drivers:
  • Increase in prevalence of cardiovascular diseases in developed regions of North America and Europe
  • Rise in demand and need for unmet atrial fibrillation drug therapy
  • Growing geriatric population in Asia Pacific and Latin America
  • Launch of Direct Oral Anticoagulants (DOACs)
Pitfalls & Challenges:
  • High cost of the anticoagulant drugs
  • Adverse drug side effects
  • Lack of awareness regarding medical therapy in underdeveloped and developing regions

Get more details on this report - Request Free Sample PDF

Atrial Fibrillation Drugs Market, By Product

Germany Atrial Fibrillation Drugs Market By Product

Get more details on this report - Request Free Sample PDF

Anticoagulant drugs market is projected to grow at 3.5% over the estimation period. Anticoagulants have been known for many years to produce a declining rate of stroke in individuals suffering from atrial fibrillation. Maximum thromboembolic perturbations of atrial fibrillation are mostly preventable with oral anticoagulants. For over fifty years, the only effective therapeutic option to prevent stroke in atrial fibrillation patients were vitamin K antagonists. Additionally, increasing focus of manufacturers in the development of oral anticoagulants have boosted the product demand. Hence, the aforementioned reasons will augment the growth of anticoagulant drugs market.

Antiarrhythmic drugs market in atrial fibrillation was valued at USD 1,384.4 million and is estimated to witness a considerable decline in the near future owing to its less effectiveness in restoring and maintaining a normal heart rhythm. It is evident that people above age of 65 years often suffer from perturbations associated with heart rhythms and hence, antiarrhythmic drug treatment is the most preferred solution in older population. But, emergence of oral anticoagulants with more effectiveness will gradually replace the use of antiarrhythmic drugs in atrial fibrillation. Thus, antiarrhythmic drugs market in atrial fibrillation will gradually decline in the near future.

 Atrial Fibrillation Drugs Market, By Atrial Fibrillation Type

The use of atrial fibrillation drugs in paroxysmal condition was valued at around USD 7,095.8 million in the year 2018. Paroxysmal atrial fibrillation occurs when an irregular and rapid heart rate starts suddenly and then stops on its own within a few days. As per the American Heart Association, currently around 2.7 million to 6 million Americans suffer from some form of atrial fibrillation. The likelihood of suffering paroxysmal atrial fibrillation rises with age. Though paroxysmal atrial fibrillation is not life-threatening, but it can cause some critical consequences with time. The most suitable prescribed treatment for paroxysmal atrial fibrillation is blood thinners or anticoagulants thus, augmenting atrial fibrillation drugs market growth.

The use of atrial fibrillation drugs for persistent condition will grow at 3.2% over the forthcoming years. Atrial fibrillation is the most common heart arrhythmia and persistent atrial fibrillation is a condition where erratic and rapid heartbeat last for longer period of time as compared to paroxysmal condition. The most preferable treatment in such cases are antiarrhythmic or anticoagulant drugs that help to restore regular heart beats and prevent blood clots, thus fueling product demand.

Atrial Fibrillation Drugs Market, By Application

Application of atrial fibrillation drugs in heart rhythm control was valued at around USD 3,312.4 million in the year 2018. Many patients suffering from atrial fibrillation require restoration of sinus rhythm to improve their quality of life. Maintenance and acute restoration of sinus rhythm in patients with atrial fibrillation are denoted as rhythm control. Antiarrhythmic drugs are generally suggested as a first-line therapy and drug prescription is done on the basis of absence or presence of structural heart disease or heart failure, renal function, and other comorbidities. It has been identified that increase in geriatric population is boosting the demand of atrial fibrillation drugs, since they are more prone to perturbations associated with heart rhythm.

Application of atrial fibrillation drugs in heart rate control will grow at 4.4% over the forecast period. Heart rate control in atrial fibrillation are to limit symptoms related with excessive heart rates and to avoid tachycardia?related cardiomyopathy. Rate control involves the use of anticoagulant drugs or surgical interventions to decrease the erratic ventricular rate often found in patients suffering from atrial fibrillation. Hence, the increasing prevalence of cardiovascular diseases have augmented the atrial fibrillation growth for heart rate control.

Atrial Fibrillation Drugs Market, By Route of Administration

Oral atrial fibrillation drug administration market was valued around USD 10,403.0 million in the year 2018. The prevalence of atrial fibrillation across the globe is increasing at a rapid pace, especially with growing age of the population. Patients with thromboembolic stroke due to atrial fibrillation have higher morbidity, mortality and longer hospital stays compared to patients with other form of strokes. The most prescribed drug therapies for the prevention of atrial strokes are oral drug therapies owing to its effectiveness in prevention of blood clotting thus, augmenting the market growth.

Injectable atrial fibrillation drugs segment is expected to witness a substantial growth at 2.4% over the projected period. The growth is attributed to its extensive use in patients suffering from atrial fibrillation who cannot take drugs orally. Hence, increase in such cases have augmented the segment growth of injectable atrial fibrillation drugs.

Atrial Fibrillation Drugs Market, By End-use

Application of atrial fibrillation drugs is highest in hospitals resulting in major market share. The hospitals segment accounted for around USD 6,583.2 million revenue in the year 2018. A substantial proportion of atrial fibrillation drug therapies happen in hospital settings; thus, demand for these drugs are the highest. During the forecast period, the hospital end-use market segment will continue to lead, owing to increasing availability of drug therapies in hospital settings coupled with rising supply agreements of drugs between manufacturing firms and hospitals.

Cardiac centers held significant industry share in 2018, being the most preferred setting in developed as well as developing countries. The cardiac centers segment is forecasted to expand at a healthy CAGR of 3.8% over the forecast period. Hence, adoption of oral drug treatments in cardiac centers should propel industry growth.

Atrial Fibrillation Drugs Market, By Region

Europe Atrial Fibrillation Drugs Market By Country

Get more details on this report - Request Free Sample PDF

U.S. dominated the North America atrial fibrillation drugs market, accounting for around USD 4,933.5 million in the year 2018. The U.S. captured the largest share of the global market due to increasing geriatric population coupled with rising prevalence of valvular diseases among the population. Moreover, increasing number of drug manufacturing companies such as Johnson and Johnson and Bristol-Myers Squibb will further augment the growth of U.S. atrial fibrillation drugs market.

China atrial fibrillation drugs market will observe rapid growth rate of 6.0% over the forecast period. The growth is attributed to development of hospitals and growing acceptance of private clinics in the region. Furthermore, prevalence of cardiac diseases due to sudden transition in lifestyle and increasing instances of binge eating have boosted the industry growth.

Competitive Market Share

Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo and AstraZeneca are some of the major industry players operating effectively in the global market. These key market participants will hold majority market share owing to strong financial position and better brand recognition. Major strategies implemented by these companies in the market include new product launches, expansion strategy, acquisition strategy etc. with the aim to gain competitive advantage over its peers.

Atrial Fibrillation Drugs Industry Background  

Atrial fibrillation is identified as one of the common cardiac diseases among individuals owing to various factors such as rise in prevalence of chronic diseases, obesity, hypertension, increasing rate of tobacco intake, alcohol consumption, coupled with high adoption rate of sedentary lifestyle among the social classes. However, clinicians introduced warfarin as the first anticoagulant drug treatment for atrial fibrillation. Although due its few shortcomings, the adoption rate had dropped, and various other anticoagulant and antiarrhythmic drugs were introduced in the market. To address the unmet needs globally, few multinational companies started investing in the research and development of atrial fibrillation drugs across the world. With ever growing need in the face of growing cardiac diseases, numerous drugs were launched in the market. Most of the atrial fibrillation diagnosed cases are in the initial stages and do not need catheter ablation, hence atrial fibrillation drugs are preferred over other treatments.

Frequently Asked Questions (FAQ) :

The market size of atrial fibrillation drugs exceeded USD 13 billion in 2018.
The industry share of atrial fibrillation drugs is expected to witness 3% CAGR from 2019 to 2025.
Occurrence of cardiovascular diseases in North America and Europe and rising demand for unmet atrial fibrillation drug therapy are slated to fuel the demand for atrial fibrillation drugs.
Increase in the number of patients suffering from atrial fibrillation needing restoration of sinus rhythm and upsurge in geriatric population are triggering the use of atrial fibrillation drugs in heart rhythm control.
Rampant valvular diseases in the U.S. and the palpable presence of leading drug manufacturing companies including Bristol-Myers Squibb and Johnson & Johnson are encouraging stakeholders to invest in North America.
Occurrence of significant number of atrial fibrillation drug therapies in hospitals and increase in supply agreements between hospitals and manufacturing firms have led to the use of atrial fibrillation drugs in hospitals.

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Premium Report Details

  • Published Date: Apr 2019
  • Pages: 350
  • Tables: 693
  • Charts / Figures: 35
  • Companies covered: 10
  • Countries covered: 40

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X